Revance Therapeutics, Inc. (RVNC) CFO Sells $297,743.88 in Stock
Revance Therapeutics, Inc. (NASDAQ:RVNC) CFO Lauren P. Silvernail sold 11,164 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $26.67, for a total transaction of $297,743.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Revance Therapeutics, Inc. (RVNC) opened at 26.10 on Thursday. Revance Therapeutics, Inc. has a 52 week low of $12.35 and a 52 week high of $28.75. The stock’s market capitalization is $804.38 million. The company’s 50 day moving average is $25.87 and its 200-day moving average is $23.63.
Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.88) earnings per share. On average, equities analysts predict that Revance Therapeutics, Inc. will post ($3.61) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Revance Therapeutics, Inc. (RVNC) CFO Sells $297,743.88 in Stock” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/19/revance-therapeutics-inc-rvnc-cfo-sells-297743-88-in-stock.html.
Large investors have recently modified their holdings of the business. Legal & General Group Plc lifted its holdings in Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 438 shares in the last quarter. Bank of America Corp DE lifted its holdings in Revance Therapeutics by 29.5% during the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 1,651 shares in the last quarter. Trexquant Investment LP purchased a new position in Revance Therapeutics during the second quarter valued at approximately $231,000. Voya Investment Management LLC purchased a new position in Revance Therapeutics during the second quarter valued at approximately $274,000. Finally, American International Group Inc. lifted its holdings in Revance Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 834 shares in the last quarter. 89.32% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of Revance Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Cantor Fitzgerald restated a “buy” rating and set a $50.00 price target on shares of Revance Therapeutics in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies set a $28.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Revance Therapeutics presently has a consensus rating of “Buy” and an average target price of $35.20.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.